...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Topics in Chemotherapy, Molecular-targeted Therapy, and Immunotherapy for Newly-diagnosed Glioblastoma Multiforme
【24h】

Topics in Chemotherapy, Molecular-targeted Therapy, and Immunotherapy for Newly-diagnosed Glioblastoma Multiforme

机译：新型胶质母细胞瘤的化学治疗，分子靶向治疗和免疫治疗主题

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glioblastoma multiforme(GBM) is the most common primary brain tumor in adults, and it is associated with poor survival. The standard therapy for newly-diagnosed GBM is radiotherapy with concurrent temozolomide following maximal surgical resection. To improve the outcome of these patients, combinations of the standard therapy plus molecular-targeted agents have been tested in clinical trials. However, the addition of gefitinib to the standard therapy did not appear to improve clinical outcome, and the standard therapy plus bevacizumab showed no improvement in overall survival, although a 4-month improvement in progression-free survival (PFS) was observed. Phase II data have indicated the potential efficacy of talampanel combined with the standard therapy for patients with newly-diagnosed GBM, and these findings are awaiting validation in phase III trials. In addition, phase II trials have demonstrated that adjuvant immunotherapy is effective and tolerable for treatment of patients with GBM. In this article, we discuss topics in chemotherapy, molecular-targeted therapy, and immunotherapy for patients with newly-diagnosed GBM.
机译：多形胶质母细胞瘤（GBM）是成人中最常见的原发性脑肿瘤，它与不良的生存率相关。新诊断的GBM的标准疗法是在最大手术切除后同时进行替莫唑胺放疗。为了改善这些患者的预后，已经在临床试验中测试了标准疗法与分子靶向药物的组合。但是，在标准疗法中加入吉非替尼似乎并未改善临床结局，尽管观察到无进展生存期（PFS）改善了4个月，但标准疗法加贝伐单抗的总体存活率并未改善。 II期数据表明，talampanel联合标准疗法对新诊断的GBM患者具有潜在的疗效，这些发现正在等待III期试验的验证。此外，II期临床试验已证明辅助免疫疗法对GBM患者有效且可耐受。在本文中，我们讨论了针对新诊断为GBM的患者的化学疗法，分子靶向疗法和免疫疗法的主题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号